Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.
Forty Cryptococcus gattii strains were submitted to antifungal susceptibility testing with fluconazole, itraconazole, amphotericin B and terbinafine. The minimum inhibitory concentration (MIC) ranges were 0.5-64.0 for fluconazole, <0.015-0.25 for itraconazole, 0.015-0.5 for amphotericin B and 0.062-2.0 for terbinafine. A bioassay for the quantitation of fluconazole in murine brain tissue was developed. Swiss mice received daily injections of the antifungal, and their brains were withdrawn at different times over the 14-day study period. The drug concentrations varied from 12.98 to 44.60 μg/mL. This assay was used to evaluate the therapy with fluconazole in a model of infection caused by C. gattii. Swiss mice were infected intracranially and treated with fluconazole for 7, 10 or 14 days. The treatment reduced the fungal burden, but an increase in fungal growth was observed on day 14. The MIC for fluconazole against sequential isolates was 16 μg/mL, except for the isolates obtained from animals treated for 14 days (MIC = 64 μg/mL). The quantitation of cytokines revealed a predominance of IFN-γ and IL-12 in the non-treated group and elevation of IL-4 and IL-10 in the treated group. Our data revealed the possibility of acquired resistance during the antifungal drug therapy.
Mendes
F E S
FE
Faculdade de Ciências da Saúde, Universidade Vale do Rio Doce, Rua Israel Pinheiro, 2000, Bairro Universitário, 35020-220 Governador Valadares, Minas Gerais, Brazil.
Oliveira
L V N
LV
Faria
E S
ES
Alvarenga
D G
DG
Pinto
M R
MR
Taborda
C P
CP
Soares
B M
BM
Cisalpino
P S
PS
Santos
D A
DA
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000382:microbiology*; D020314:Central Nervous System Fungal Infections / Q000188:drug therapy* / Q000382:microbiology; D003453:Cryptococcosis / Q000188:drug therapy* / Q000382:microbiology; D056285:Cryptococcus gattii / Q000187:drug effects*; D004195:Disease Models, Animal; D025141:Drug Resistance, Fungal; D015725:Fluconazole / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D016896:Treatment Outcome
D000935:Antifungal Agents; D015725:Fluconazole
Antimicrob Agents Chemother. 2004 Mar;48(3):985-91
14982793
J Antimicrob Chemother. 1999 Jun;43(6):817-24
10404321
FEMS Yeast Res. 2007 Jan;7(1):152-64
17311593
J AOAC Int. 2009 Jul-Aug;92(4):1076-81
19714975
Rev Iberoam Micol. 2002 Sep;19(3):133-8
12825990
Antimicrob Agents Chemother. 2007 Aug;51(8):3011-3
17562797
Antimicrob Agents Chemother. 2005 Aug;49(8):3297-301
16048939
Int J Antimicrob Agents. 2009 Jun;33(6):559-63
19195846
Rev Iberoam Micol. 2008 Dec 31;25(4):242-5
19071894
FEMS Yeast Res. 2009 Mar;9(2):301-10
19220870
Int J Pharm. 2005 Jan 6;288(1):81-6
15607260
Infect Immun. 2009 Mar;77(3):1061-70
19114546
Antimicrob Agents Chemother. 1989 May;33(5):714-6
2546489
Antimicrob Agents Chemother. 1996 Aug;40(8):1935-7
8843308
Clin Infect Dis. 2004 Oct 15;39(8):e78-82
15486830
J Infect Dis. 2005 Aug 15;192(4):681-4
16028138
Mol Microbiol. 2003 Jan;47(2):357-71
12519188
Antimicrob Agents Chemother. 1998 Mar;42(3):528-33
9517927
Infect Immun. 2006 Feb;74(2):896-903
16428732
Antimicrob Agents Chemother. 1996 Sep;40(9):2178-82
8878602
J Pharm Biomed Anal. 2006 Feb 13;40(2):443-6
16139980
Mycoses. 2007 Jul;50(4):286-9
17576321
Antimicrob Agents Chemother. 1996 Mar;40(3):822-4
8851624
Mycopathologia. 2007 Jul;164(1):27-33
17551848
Clin Microbiol Infect. 2008 Jul;14(7):727-30
18558948
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):174-9
17275423
Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):256-70
15015031
Rev Iberoam Micol. 2008 Sep 30;25(3):150-3
18785783